CEL-SCI (NYSE:CVM) Stock Rating Lowered by StockNews.com

CEL-SCI (NYSE:CVM) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

CEL-SCI Price Performance

Shares of CEL-SCI stock opened at $0.64 on Wednesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. CEL-SCI has a 52-week low of $0.54 and a 52-week high of $3.23. The company has a fifty day moving average of $0.95 and a 200-day moving average of $1.13. The stock has a market capitalization of $40.83 million, a price-to-earnings ratio of -1.10 and a beta of 0.69.

Institutional Investors Weigh In On CEL-SCI

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tidal Investments LLC purchased a new position in CEL-SCI in the 1st quarter worth approximately $27,000. Calton & Associates Inc. bought a new stake in CEL-SCI during the 3rd quarter valued at $50,000. Black Diamond Financial LLC boosted its position in CEL-SCI by 35.8% during the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after buying an additional 19,000 shares during the period. Plotkin Financial Advisors LLC bought a new stake in CEL-SCI in the 3rd quarter worth $98,000. Finally, Cutter & CO Brokerage Inc. boosted its holdings in shares of CEL-SCI by 29.4% during the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after purchasing an additional 24,634 shares during the period. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.